These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 25324168)

  • 1. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
    Kato Y
    Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
    Kato Kaneko M; Ogasawara S; Kato Y
    Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
    Kato Y; Natsume A; Kaneko MK
    Biochem Biophys Res Commun; 2013 Mar; 432(4):564-7. PubMed ID: 23485467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
    Kaneko MK; Morita S; Tsujimoto Y; Yanagiya R; Nasu K; Sasaki H; Hozumi Y; Goto K; Natsume A; Watanabe M; Kumabe T; Takano S; Kato Y
    Biochem Biophys Res Commun; 2013 Mar; 432(1):40-5. PubMed ID: 23376717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations.
    Kaneko MK; Tsujimoto Y; Hozumi Y; Goto K; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2013 Jun; 32(3):224-8. PubMed ID: 23750482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
    Liu X; Ogasawara S; Kaneko MK; Oki H; Hozumi Y; Goto K; Takagi M; Kato Y
    Biochem Biophys Res Commun; 2015 Apr; 459(4):636-42. PubMed ID: 25753205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation.
    Kaneko MK; Tian W; Takano S; Suzuki H; Sawa Y; Hozumi Y; Goto K; Yamazaki K; Kitanaka C; Kato Y
    Biochem Biophys Res Commun; 2011 Mar; 406(4):608-13. PubMed ID: 21352804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
    Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
    Kato Kaneko M; Liu X; Oki H; Ogasawara S; Nakamura T; Saidoh N; Tsujimoto Y; Matsuyama Y; Uruno A; Sugawara M; Tsuchiya T; Yamakawa M; Yamamoto M; Takagi M; Kato Y
    Cancer Sci; 2014 Jun; 105(6):744-8. PubMed ID: 24898068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations.
    Ogasawara S; Kaneko MK; Tsujimoto Y; Liu X; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2013 Dec; 32(6):377-81. PubMed ID: 24328739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.
    Kato Y; Jin G; Kuan CT; McLendon RE; Yan H; Bigner DD
    Biochem Biophys Res Commun; 2009 Dec; 390(3):547-51. PubMed ID: 19818334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.
    Takano S; Kato Y; Yamamoto T; Liu X; Ishikawa E; Kaneko MK; Ogasawara S; Matsuda M; Noguchi M; Matsumura A
    Brain Tumor Pathol; 2015 Jul; 32(3):169-75. PubMed ID: 25652153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
    Liu X; Kato Y; Kaneko MK; Sugawara M; Ogasawara S; Tsujimoto Y; Naganuma Y; Yamakawa M; Tsuchiya T; Takagi M
    Cancer Med; 2013 Dec; 2(6):803-14. PubMed ID: 24403254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.
    Gondim DD; Gener MA; Curless KL; Cohen-Gadol AA; Hattab EM; Cheng L
    Appl Immunohistochem Mol Morphol; 2019; 27(10):722-725. PubMed ID: 30358614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate dehydrogenase mutations in gliomas.
    Waitkus MS; Diplas BH; Yan H
    Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma.
    Hayashi A; Misumi K; Shibahara J; Kokudo N; Kato Y; Fukayama M
    Pathol Int; 2016 Oct; 66(10):578-582. PubMed ID: 27595804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
    Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
    Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
    Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1‑mutant tumor cells.
    Zhang Y; Lv W; Li Q; Wang Q; Ru Y; Xiong X; Yan F; Pan T; Lin W; Li X
    Mol Med Rep; 2019 Aug; 20(2):1893-1900. PubMed ID: 31257503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.